Merck, a life science leader, is a business of Merck KGaA, Darmstadt, Germany. Our products and services help you safely, efficiently develop and manufacture therapeutics. Our BioReliance® Biosafety Testing Services offer best-in-class, risk mitigating solutions with technical and regulatory expertise to help you bring life-changing drugs to market. Our comprehensive and integrated testing and manufacturing services span the product cycle from early pre-clinical development to licensed production. Partner with us for innovative biosafety testing, analytical development, and biomanufacturing services.

Your Therapy, Our Priority
Your Trusted Partner for Innovative Biosafety Testing, Viral Clearance & Product Characterization

Have a Question ?
Let’s connect and speak to our team of Technical and Regulatory expertise
Email: BiosafetyAP@merckgroup.com

Visit and learn more:
WWW.SIGMAALDRICH.COM/BIOSAFETYTESTING

【デモセッション　7月12日12:40-12:55】
スピーカー：Dr Edmund Ang
タイトル：The Blazar®platform for Rapid Broad Spectrum Adventitious Virus Detection

Traditional testing approaches for broad spectrum detection of adventitious viruses of concern in the manufacturing of biologics typically include in vivo and/or in vitro methods that can take up to several weeks to perform, in addition to potential challenges due to test sample suitability particularly with ATMP and other novel modalities.
The Blazar® platform is developed to combine the speed and sensitivity of PCR with the breath of target detection akin to next generation sequencing (NGS). The Blazar® assay is based on degenerate PCR approach to amplify multiple targets within conserved regions of virus families, followed by target specific nested PCR and high resolution amplicon sizing detection, to enable a rapid and highly sensitive detection of panels of viruses of interest in just days. Two Blazar® assays, Rodent Panel and CHO AOF, are already available and a pipeline of other assays in development to advance biologics QC testing.